Table 3 Univariate and multivariate Cox proportional hazards regression models for overall survival in patients with EOC

Age

 < 55

Ref

 ≥ 55

0.006*

5.06—23.75

0.365

0.68—2.84

FIB

 < 4.23

Ref

 ≥ 4.23

0.275

0.79—2.28

Leukocyte

 < 6.63

Ref

 ≥ 6.63

0.138

0.88—2.55

CA125

 < 325.95

Ref

 ≥ 325.95

 < 0.001*

5.06—23.73

0.071

0.93—6.32

CA199

 < 13.13

Ref

 ≥ 13.13

0.009*

0.28—0.83

0.003*

0.17—0.70

HE4

 < 244.5

Ref

 ≥ 244.5

 < 0.001*

3.58—17.48

0.028*

1.12—7.46

CEA

 < 1.84

Ref

 ≥ 1.84

0.563

0.50—1.45

ALB

 < 41.55

Ref

 ≥ 41.55

 < 0.001*

0.13—0.44

1.000

0.35—2.82

FIGO Stage

 I/II

Ref

 III/IV

 < 0.001^*

6.15–27.30

0.009*

1.43–12.46

Laterality

 Unilateral

Ref

 Bilateral

 < 0.001*

1.48—4.34

0.067

0.28—1.04

Lymph nodes metastasi

 Negative

Ref

 Postive

 < 0.001*

0.13—0.39

0.258

0.73—3.27

Vascular infiltration

 Negative

Ref

 Postive

 < 0.001*

0.16—0.56

0.665

0.54—2.62

Residual disease

 Negative

Ref

 Postive

 < 0.001*

0.14—0.49

0.022*

1.18—8.58

Specimen incisal margin

 Negative

Ref

 Postive

 < 0.001*

0.11—0.35

 < .001*

2.22—14.29

Ascites

 Negative

Ref

 Postive

 < 0.001*

0.06—0.28

0.003*

1.86—18.98

Ascites exfoliation cytology

 Negative

Ref

 Postive

 < 0.05*

0.29—0.84

0.071

0.95—3.90

SII

 < 998.87

Ref

 ≥ 998.87

 < 0.001*

3.67–15.49

0.034*

1.09—8.81

PNI

 < 49.75

Ref

 ≥ 49.75

 < 0.001*

0.03—0.17

0.013*

0.06—0.71

PLR

 < 217.63

Ref

 ≥ 217.63

 < 0.001*

3.2—11.3

0.451

0.30—1.70

NLR

 < 2.61

Ref

 ≥ 2.61

 < 0.001*

5.11—52.56

0.258

0.54—9.94